The Role of Imaging in Diagnosing and Staging Prostate Cancer

A panel of experts on prostate cancer introduce themselves and begin the discussion with clinical insights on diagnostic practices and the importance of biopsy and imaging in guiding treatment decisions.

Now Viewing

EP: 1.The Role of Imaging in Diagnosing and Staging Prostate Cancer

EP: 2.Advances in Prostate Biopsy

EP: 3.Benefits of Incorporating Fusion-Guided Biopsy into Practice

EP: 4.A Review of the Data for Fusion-Based Biopsy Procedures

EP: 5.Understanding Differences in Fusion-Guided Biopsy Technologies

EP: 6.The Role for Systematic Biopsy Plus MRI-Targeted Procedures

EP: 7.Fusion-Guided Biopsies in Active Surveillance for Patients With Prostate Cancer

EP: 8.Using Fusion-Guided Biopsy to Determine Eligibility for Focal Therapy

EP: 9.Incorporating Fusion-Guided Biopsy to Practice

EP: 10.Future Directions for Imaging and Biopsy in Prostate Cancer

EP: 11.The Impact of MRI-Guided Biopsy in Diagnosis and Treatment Decisions

EP: 12.Overcoming Limitations of Traditional Biopsies with MRI-Guided Biopsies

EP: 13.An Overview of Fusion-Guided Systems

EP: 14.Fusion-Based Biopsies in Active Surveillance

EP: 15.Expert Insights on MRI-US Fusion-Guided Biopsy

EP: 16.The Impact of Fusion-Guided Biopsy on Focal Therapy in Prostate Cancer

EP: 17.Looking Ahead: Image-Guided Diagnostic Tools

Related Videos

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke

Pluvicto was approved by Health Canada in August 2022.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke

Pluvicto was approved by Health Canada in August 2022.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.